The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the ...

Anne Wojcicki, co-founder and former CEO of 23andMe, has bid to buy back the genetic testing platform, which was pronounced ...

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

Regeneron and Sanofi are committed to helping patients in the U.S. who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay® program. For ...

Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

This was the stock's second consecutive day of losses.

Regeneron Inc. seeks to disqualify Kirkland & Ellis from representing its opponent Novartis AG in a major antitrust and ...

The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...

This trial evaluated the safety and efficacy of the combination of Regeneron’s Lynozyfic (linvoseltamab), a B-cell maturation ...

Regeneron is backing away from buying the DNA-testing company after a nonprofit controlled by co-founder Wojcicki made a ...

Regeneron Pharmaceuticals was outbid in its effort to buy 23andMe by a nonprofit led by the bankrupt genetics testing company’s co-founder. California-based TTAM Research Institute, led by Anne ...

This was the stock's second consecutive day of gains.